Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Vention to democratize industrial automation using NVIDIA AI technologies
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
-
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
RentFinder.ai Sets New Standards in Rental Estimates, Achieves 250% Surge in Usage
-
Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
-
June Joy at Juicy Stakes Casino
-
Accelerate Your Establishment Forward By Implementing These Simple Corporate Hacks
-
Exploring The Main Aspects To Consider When Eradicating Pesky Pests From Your Home
-
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
Top 10 Compelling Reasons Why Your Kids Should Have Regular School Physicals
-
Odyssey Capital participated in the Washington D.C. Blockchain Summit, proposing the establishment of a Global Special Assets Alliance Fund initiative.
-
Are Ruby Gemstones Worth Investing In?
-
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
-
Capsucup: Where Quality and Sustainability Meet in Italian Espresso
-
Leading Contractor Marketing Agency Webrunner Media Broadens Service Portfolio
-
Xfive Recognized as a Clutch Global Leader for Spring 2024
-
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
-
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
-
Eyes Defined Introduces 3D Images to Revolutionize Eyelid Surgery Planning
-
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
-
Goat Token A must have rising star in the crypto world
-
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
-
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaka' at the UEFA Champions League Final 2024
-
OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaká at the UEFA Champions League Final 2024
-
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
-
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever
-
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
-
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
-
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
-
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a La
-
Quebec Precious Metals Announces First Closing of a Private Placement
-
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
-
Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
